NCT00165646 - A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease | Biotech Hunter

Enrollment

288

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

October 31, 2005

Study Completion Date

October 31, 2005

Conditions

Non-erosive Gastroesophageal Reflux Disease

Interventions

DRUG

E3810

E3810 5mg: once daily orally for 4 weeks

DRUG

E3810

E3810 10mg: once daily orally for 4 weeks

DRUG

Placebo

Placebo: once daily orally for 4 weeks

Trial Locations (35)

480-1103

Aichi-Gun

466-0065

Nagoya

467-0001

Nagoya

818-0024

Chikushino-shi

818-0067

Chikushino-shi

813-0003

Fukuoka

807-1262

Kitakyushu

371-0034

Maebashi

730-0052

Hiroshima

734-0037

Hiroshima

003-0021

Sapporo

060-0061

Sapporo

060-0814

Sapporo

780-0901

Kochi

602-0000

Kyoto

606-8397

Kyoto

980-0872

Sandai

984-0075

Sendai

570-0021

Moriguchi

530-0012

Osaka

536-0002

Osaka

545-0051

Osaka

849-0937

Saga

332-0021

Kawaguchi

693-0021

Izumo

690-0886

Matsue

431-3125

Hamamatsu

140-0011

Shinagawa-ku

162-0052

Shinjuku-ku

756-0076

Sanyōonoda

757-0002

Sanyōonoda

755-0004

Ube

755-0046

Ube

755-0067

Ube

755-0077

Ube

All Listed Sponsors

lead

Eisai Co., Ltd.

INDUSTRY